An extension trial to a phase I dose escalation study of LBQ707 (gimatecan) administered orally 5 consecutive days to Japanese patients with advanced solid tumor.
Phase of Trial: Phase I
Latest Information Update: 30 Apr 2012
At a glance
- Drugs Gimatecan (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 02 Jul 2010 Actual patient number (4) added as reported by ClinicalTrials.gov.
- 02 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Jul 2010 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.